tiprankstipranks
Analyst Profile
Followed by 270 other investors
.
Paul Matteis

Paul Matteis

Stifel Nicolaus
Wall Street Analyst
Ranked #960 out of 8,047 Analysts on TipRanks (#1,634 out of 21,521 overall experts)

Success Rate

50%
126 out of 254 Profitable Transactions

Average Return

9.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Paul Matteis's ratings since 2016 and opened each position for the duration of 1 Year:
49.61% of your transactions would have been profitable with an average return of 9.7%

Stock Rating Distribution

461Ratings
66.38% Buy
33.62% Hold
0.00% Sell
Distribution of Paul Matteis's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Zogenix
(ZGNX)
Rating Type:Buy
Dates:Nov 07, 2016 - Nov 07, 2017
Gain:387.10%
The most profitable rating made by Paul Matteis

Paul Matteis's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Tempest Therapeutics
Hold
Reiterated
$7.00
(225.58% Upside)
0.00%
2
Ignyta Inc
Buy
Reiterated
100%
+8.05%
3
Calithera Bio
Buy
Reiterated
$11.00
(167.64% Upside)
50%
+64.15%
3
OncoMed Pharma
Hold
Reiterated
0.00%
4
Orexigen
Hold
Reiterated
0%
-76.40%
10
Fate Therapeutics
Buy
Reiterated
75%
+71.25%
4
Theravance Biopharma
Buy
Reiterated
$29.00
(201.77% Upside)
100%
+89.35%
5
Melinta Therapeutics
Hold
Assigned
0.00%
4
Sio Gene Therapies
Buy
Reiterated
100%
+58.50%
2
Neoleukin Therapeutics
Buy
Reiterated
$24.00
(1933.90% Upside)
50%
+11.15%
7
List of latest recommendations made by Paul Matteis. Click to expand and see Paul Matteis's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More